Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 203-210

  Propper, D J ^a   De Bono, J ^a   Saleem, A ^a   Ellard, S ^a   Flanagan, E ^a   Paul, J ^a   Ganesan, T S ^a   Talbot, D C ^a   Aboagye, E O ^a   Price, P ^a   Harris, A L ^a   Twelves, C ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; UNCLASSIFIED DRUG; XR 5000; ACRIDINE DERIVATIVE; CARBON; DACA, ACRIDINE; DIAGNOSTIC AGENT;

ABDOMINAL PAIN; ADENOCARCINOMA; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; HEALTH CARE ORGANIZATION; HUMAN; MAXIMUM ALLOWABLE CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; THORAX PAIN; TREATMENT RESPONSE; VOMITING; ADULT; AGED; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSE RESPONSE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; SCINTISCANNING; TISSUE DISTRIBUTION;

ACRIDINES; ADULT; AGED; AREA UNDER CURVE; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037440039     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.008     Document Type: Article

References (28)

1. Finlay GJ, Riou JF, Baguley BC: From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 32A:708-714, 1996
2. Bridewell DJ, Finlay GJ, Baguley BC: Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: The roles of topoisomerases I and II. Cancer Chemother Pharmacol 43:302-308, 1999
3. Davey RA, Su GM, Hargrave RM, et al: The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemother Pharmacol 39:424-430, 1997
4. Finlay GJ, Marshall E, Matthews JH, et al: In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 31:401-406, 1993
5. Vasey PA, Kaye SB: Combined inhibition of topoisomerases I and II-Is this a worthwhile/feasible strategy? Br J Cancer 76:1395-1397, 1997
6. Baguley BC, Zhuang L, Marshall E: Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemother Pharmacol 36:244-248, 1995
7. Atwell GJ, Rewcastle GW, Baguley BC, et al: Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide. J Med Chem 30:664-669, 1987
8. XR5000: Clinical Investigator's Brochure. Slough, U.K., Xenova Group, 1997
9. Cornford EM, Young D, Paxton JW: Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs. Cancer Chemother Pharmacol 29:439-444, 1992
10. Paxton JW, Young D, Evans SM, et al: Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse. Cancer Chemother Pharmacol 32:320-322, 1993
11. Paxton JW, Young D, Evans SM, et al: Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse. Cancer Chemother Pharmacol 29:379-384, 1992
12. Twelves CJ, Gardner C, Flavin A, et al: Phase I and pharmacokinetic study of DACA (XR5000): A novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee. Br J Cancer 80:1786-1791, 1999
13. McCrystal MR, Evans BD, Harvey VJ, et al: Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 44:39-44, 1999
14. Kestell P, Dunlop IC, McCrystal MR, et al: Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial. Cancer Chemother Pharmacol 44:45-50, 1999
15. Evans SM, Robertson IG, Paxton JW: Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. J Pharm Pharmacol 46:63-67, 1994
16. Finlay GJ, Baguley BC: Selectivity of N-[2-(dimethylamino)ethyl]acridine- 4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. Eur J Cancer Clin Oncol 25:271-277, 1989
17. Haldane A, Finlay GJ, Gavin JB, et al: Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 29:475-479, 1992
18. Turnbull RM, Meczes EL, Perenna Rogers M, et al: Carbamate analogues of amsacrine active against non-cycling cells: Relative activity against topoisomerases IIalpha and beta. Cancer Chemother Pharmacol 44:275-282, 1999
19. Goswami PC, Roti Roti JL, Hunt CR: The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation. Mol Cell Biol 16:1500-1508, 1996
20. Joel SP, Slevin ML: Schedule-dependent topoisomerase II-inhibiting drugs. Cancer Chemother Pharmacol 34:S84-88, 1994
21. Harte RJ, Matthews JC, O'Reilly SM et al: Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol 17:1580-1588, 1999
22. Saleem A, Yap J, Osman S, et al: Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 355:2125-2131, 2000
23. Saleem A, Harte RJ, Matthews JC, et al: Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 19:1421-1429, 2001
24. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
25. Brady F, Luthra SK, Brown G, et al: Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man. Appl Radiat Isot 48:487-492, 1997
26. Brooks RA, Di Chiro G: Theory of image reconstruction in computed tomography. Radiology 117:561-572, 1975
27. Robb RA, Hanson DP: A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med 14:9-30, 1991
28. Schneider E, Darkin SJ, Lawson PA, et al: Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine- 4-carboxamide: Role of DNA topoisomerase II. Eur J Cancer Clin Oncol 24:1783-1790, 1988